Fresenius Medical Care AG confirmed earnings guidance for the fiscal year 2024. For the year, the company expected revenue to grow by a low- to mid-single digit percent rate compared to prior year. The Company expected operating income to grow by a mid- to high-teens percent rate compared to prior year.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
38.35 EUR | -2.47% | -1.03% | +1.03% |
May. 28 | FMC briefly burdened by research success in the fight against diabetes | DP |
May. 28 | FMC FRESENIUS MEDICAL CARE AG & CO KGAA : Berenberg reaffirms its Buy rating | ZD |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+1.03% | 12.55B | |
+20.12% | 83.46B | |
-2.68% | 25.66B | |
+3.31% | 17.91B | |
-15.31% | 16.54B | |
+0.22% | 15.43B | |
+75.22% | 13.46B | |
+74.08% | 12.78B | |
+40.02% | 12.6B | |
-3.27% | 12.33B |
- Stock Market
- Equities
- FME Stock
- News Fresenius Medical Care AG
- Fresenius Medical Care Ag Confirms Earnings Guidance for the Fiscal Year 2024